Dan Yi
- Rheumatology top 5%
- Nephrology top 5%
- Dialysis and Renal Disease Management 5
- Cancer Research top 10%
-
- Extracellular vesicles in disease 6
- Protein Interaction Studies and Fluorescence Analysis 3
- RNA modifications and cancer 3
- Bone Metabolism and Diseases 3
-
- Pulmonary Hypertension Research and Treatments 7
-
- Nerve injury and regeneration 5
-
- Cardiovascular Function and Risk Factors 4
- Partner nations
- ChinaUnited StatesFrance
In The Last Decade
Dan Yi
67 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 115
- Rheumatology 239
- Nephrology 96
- Cancer Research 196
- Complementary and Manual Therapy 27
- Molecular Biology 666
Countries citing papers authored by Dan Yi
This map shows the geographic impact of Dan Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Yi more than expected).
Fields of papers citing papers by Dan Yi
This network shows the impact of papers produced by Dan Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Yi. The network helps show where Dan Yi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Dan Yi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 38 | |
| 6 | 2023 | 9 | |
| 7 | 2023 | 5 | |
| 8 | 2023 | 17 | |
| 9 | 2023 | 10 | |
| 10 | 2023 | 1 | |
| 11 | 2022 | 3 | |
| 12 | 2022 | 19 | |
| 13 | 2021 | 70 | |
| 14 | 2020 | 26 | |
| 15 | 2018 | 7 | |
| 16 | 2014 | 29 | |
| 17 | 2014 | 124 | |
| 18 | 2013 | 42 | |
| 19 | Inhibition of 22 kinds of Chinese herbs on α-glucosidase in vitro | 2010 | 1 |
| 20 | Effect of sinomenine gel on adjuvant arthritis in rats | 2002 | 1 |
About Dan Yi
Dan Yi is a scholar working on Complementary and Manual Therapy, Nephrology, Molecular Biology, Cancer Research and Developmental Biology, having authored 71 papers that have together received 1.4k indexed citations. Recurring topics across this work include Pulmonary Hypertension Research and Treatments (7 papers), Extracellular vesicles in disease (6 papers), Dialysis and Renal Disease Management (5 papers), Nerve injury and regeneration (5 papers), Cardiovascular Function and Risk Factors (4 papers), Protein Interaction Studies and Fluorescence Analysis (3 papers), RNA modifications and cancer (3 papers) and Bone Metabolism and Diseases (3 papers). The work is most often cited by research in Rheumatology (239 citations), Nephrology (96 citations), Cancer Research (196 citations), Complementary and Manual Therapy (27 citations) and Molecular Biology (666 citations). Dan Yi has collaborated with scholars based in China, United States and France. Frequent co-authors include Ke Lu, Di Chen, Christophe O. Soulage, Guozhi Xiao, Liping Tong, Jinge Xin, Kangcheng Pan, Hesong Wang, Xueqin Ni and Huan Yu. Their work appears in journals such as Biochimie, Kidney International, Frontiers in Plant Science, Journal of the European Academy of Dermatology and Venereology and International Journal of Molecular Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.